Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
Pharma News
Yposkesi set to double capacity and become a viral vector force
With demand for viral vectors far exceeding supply, manufacturers are rushing to fill the void.
Biogen’s ambitions in gene therapy hit by another failed pivotal trial
When Biogen acquired Nightstar Therapeutics in 2019, it added a pair inherited retinal disorder (IRD) gene therapies that it hoped would accelerate a push into the fast-evolving category.
FDA approves avapritinib for advanced systemic mastocytosis
On June 16, 2021, the Food and Drug Administration approved avapritinib (Ayvakit™, Blueprint Medicines Corp.
Researchers in Ireland identify the reason COVID-19 patients develop blood clots
Scientists in Ireland have identified how and why some COVID-19 patients can develop life-threatening clots, which could lead to targeted therapies that prevent this from happening.
AstraZeneca's antibody cocktail fails to prevent Covid-19 in latest trial
AstraZeneca Plc’s antibody cocktail was only 33% effective at preventing Covid-19 symptoms in people who had been exposed to the virus, failing a study that was key to the drugmaker’s pandemic...
Monoclonal antibodies cut risk of dying from COVID-19 — but only in some patients
The world’s largest trial of COVID-19 therapeutics has for the first time produced convincing evidence that a therapy that directly attacks the virus can save hospitalized patients from death.
NIH study offers new evidence of early SARS-CoV-2 infections in U.S.
A new antibody testing study examining samples originally collected through the National Institutes of Health’s All of Us Research Program found evidence of SARS-CoV-2 infections in five states earl...
Novavax COVID vaccine 90% effective in phase 3 trial
Novavax's two-dose COVID-19 vaccine showed 90% overall vaccine efficacy (VE), 100% protection against moderate and severe illness, and 93% VE against variants of concern and of...
FDA launches global Generic Drug Cluster
In a new effort to boost alignment of scientific and regulatory approaches to generic drug development among global regulators, the US Food and Drug Administration is standing up a Generic Drug Cluste...
AstraZeneca, Daiichi Sankyo launch Enhertu head-to-head trial with eyes on a new breast cancer standard
AstraZeneca and Daiichi Sankyo have high hopes for their HER2-targeted drug Enhertu and are planning a long list of clinical trials in several diseases to capitalize on its multibillion-dollar potenti...
Biogen's $56K price on Aduhelm 'simply unacceptable,' Alzheimer's Association says after vouching for FDA approval
Biogen’s decision to price its historic Alzheimer’s drug Aduhelm at a whopping $56,000 per year unsurprisingly irked lawmakers in Washington D.
New super-resolution technique allows for more detailed brain imaging
A new imaging technique has the potential to detect neurological disorders -- such as Alzheimer's disease -- at their earliest stages, enabling physicians to diagnose and treat patients more quick...
221
222
223
224
225
226
227
228
229
